What to do if ovarian cancer recurs

To reduce the recurrence of ovarian cancer, correct treatment is necessary, and the presence of recurrence factors should be avoided after treatment. What should be done if ovarian cancer recurs? To avoid recurrence, the lesions must be completely removed. During ovarian cancer surgery, the primary tumor and the visible pelvic and abdominal metastases should be removed as much as possible, or the diameter of the residual cancer lesions should be less than 2.0 to 1.5 meters. For epithelial cancer, the greater omentum and appendix should also be removed. At the same time, to prevent the recurrence of ovarian cancer, long-term chemotherapy must be insisted. Chemotherapy for ovarian cancer should be long-term and continuous, especially for those in the late stage and those who cannot be removed by surgery.

At the same time, medication is also very important. You must follow the doctor's advice, do not abuse drugs, do not increase or decrease the dosage at will, etc. You must follow the medication plan: the first year after surgery: one course of treatment per month; the second year: one course of treatment per month; the third year: one course of treatment every 6 months; the fourth to fifth year: one course of treatment every 6 months, mostly oral medication. Change according to clinical stage, tissue differentiation, completeness of surgical resection, patient response, etc. After 5 years, if there is no sign of recurrence, you can stop taking the medication. Try to avoid stopping chemotherapy midway, as stopping chemotherapy midway can increase the possibility of recurrence of ovarian malignant tumors.

What should I do if ovarian cancer recurs? To prevent the recurrence of ovarian cancer, we must pay attention to the auxiliary treatment of traditional Chinese medicine. Modern research shows that the use of traditional Chinese medicine in the treatment of patients with ovarian malignant tumors can have two effects. One is to inhibit and kill cancer cells, and the other is to enhance the host's immunity. These effects are beneficial to patients' preoperative control of the disease and postoperative prevention of recurrence. Promoting autoimmunity will be a means of reducing the recurrence of ovarian cancer in clinical treatment.